- Home
- GRX vs DMAC Comparison
GRX vs DMAC Comparison
Compare GRX & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- DMAC
- Stock Information
- Founded
- GRX 2007
- DMAC 2000
- Country
- GRX United States
- DMAC United States
- Employees
- GRX N/A
- DMAC N/A
- Industry
- GRX Finance/Investors Services
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- GRX Finance
- DMAC Health Care
- Exchange
- GRX Nasdaq
- DMAC Nasdaq
- Market Cap
- GRX 154.8M
- DMAC 158.1M
- IPO Year
- GRX N/A
- DMAC N/A
- Fundamental
- Price
- GRX $9.56
- DMAC $4.11
- Analyst Decision
- GRX
- DMAC Strong Buy
- Analyst Count
- GRX 0
- DMAC 2
- Target Price
- GRX N/A
- DMAC $8.00
- AVG Volume (30 Days)
- GRX 39.7K
- DMAC 102.4K
- Earning Date
- GRX 01-01-0001
- DMAC 05-13-2025
- Dividend Yield
- GRX 5.98%
- DMAC N/A
- EPS Growth
- GRX N/A
- DMAC N/A
- EPS
- GRX 0.26
- DMAC N/A
- Revenue
- GRX N/A
- DMAC N/A
- Revenue This Year
- GRX N/A
- DMAC N/A
- Revenue Next Year
- GRX N/A
- DMAC N/A
- P/E Ratio
- GRX $38.50
- DMAC N/A
- Revenue Growth
- GRX N/A
- DMAC N/A
- 52 Week Low
- GRX $7.73
- DMAC $2.14
- 52 Week High
- GRX $10.40
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- GRX 51.27
- DMAC 50.90
- Support Level
- GRX $9.43
- DMAC $3.92
- Resistance Level
- GRX $9.56
- DMAC $4.33
- Average True Range (ATR)
- GRX 0.12
- DMAC 0.29
- MACD
- GRX 0.02
- DMAC 0.02
- Stochastic Oscillator
- GRX 86.96
- DMAC 56.79
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.